International Myeloma Society Annual Meeting

The 2024 International Myeloma Society Annual Meeting was a groundbreaking event that showcased the latest advancements in multiple myeloma research and treatment.

Belantamab mafodotin plus pomalidomide and dexamethasone showed significant progression-free survival benefits and maintained quality of life in patients with relapsed/refractory multiple myeloma, as demonstrated in the DREAMM-8 trial.

A single infusion of the autologous GPRC5D-targeted CAR T-cell therapy BMS-986393 led to high response rates in patients with relapsed/refractory multiple myeloma who received between 1 and 3 prior lines of therapy.

A real-world analysis of cilta-cel in patients with relapsed/refractory multiple myeloma showed deep and durable responses, with a safety profile consistent with clinical trial data.

A new study found that adding daratumumab to lenalidomide, bortezomib, and dexamethasone significantly improved outcomes for older patients with newly diagnosed multiple myeloma.

A new combination therapy involving sonrotoclax and dexamethasone demonstrated safety, antitumor activity, and early responses in heavily pretreated patients with relapsed/refractory multiple myeloma harboring t(11:14).

A novel, all-oral combination regimen of mezigdomide, tazemetostat, and dexamethasone demonstrated early signals of activity and a tolerable safety profile in patients with highly refractory multiple myeloma.

A new combination therapy involving belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone showed promising results in patients with multiple myeloma who had received 1 prior line of therapy.

A new allogeneic CAR T-cell therapy, P-BCMA-ALLO1, has shown promising results in treating heavily pretreated patients with relapsed/refractory multiple myeloma.

The CARTITUDE-4 study found that cilta-cel reduced the risk of death by 45% compared to standard of care in patients with multiple myeloma.

Ashraf Z. Badros, MB, ChB, discusses the key takeaways from the phase 3 AURIGA trial.

A study found that anito-cel is a promising CAR T-cell therapy for relapsed/refractory multiple myeloma with high efficacy and manageable safety.

A new CAR T-cell therapy, durcabtagene autoleucel, showed promising results in treating relapsed/refractory multiple myeloma with high response rates and manageable adverse effects.

Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, offering a promising approach to deeper disease response.

Maintenance therapy with daratumumab and lenalidomide led to higher MRD-negative conversion rates compared to lenalidomide alone in newly diagnosed multiple myeloma patients following transplant.

Isa-KRd showed deep responses, high MRD negativity rates, and manageable safety in patients with newly diagnosed, transplant-eligible multiple myeloma, as per interim analysis of the IFM2020-02 MIDAS study.

In TRIMM-2, an overall response rate of 82% was seen amon patients given talquetamab plus daratumumab and pomalidomide in patients with relapsed/refractory multiple myeloma.

Binod Dhakal, MD, MS, discusses some of the challenges often seen in the myeloma space, particularly those with lenalidomide-refractory multiple myeloma.

A new drug combination, talquetamab and teclistamab, shows promising results in treating patients with heavily pretreated multiple myeloma, with high response rates and durable responses.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the phase 3 CEPHEUS trial of daratumumab with bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

Positive response and preliminary evidence of longer progression-free survival was observed with a venetoclax-based triplet therapy vs a doublet, in a phase. 2 study.

The observed benefits of ciltacabtagene autoleucel in patients with multiple myeloma and poor prognostic features are consistent with the overall the population of CARTITUDE-4.

NXC-201 has demonstrated safety and elicited hematologic and organ responses in patients with relapsed/refractory amyloid light chain amyloidosis, including frail patients.

In the phase 3 CARTITUDE-4 trial, ciltacabtagene autoleucel was shown to be effective when used in patients with multiple myeloma exhibiting poor prognostic features.

IberVd showed high efficacy with deep, ongoing responses among older patients with transplant-ineligible, newly diagnosed multiple myeloma.

Researchers identified KDM6A’s role in CD38 regulation and found that an EZH2 inhibitor could potentially reduce resistance to an anti-CD38 antibody in multiple myeloma cells.

Although response rates were lower among patients given previous anti-BCMA therapy, teclistamab shows promise for all patients with relapsed/refractory multiple myeloma.

At a median duration of response of 12.2 months, the objective response rates with forimtamig across all dose levels was 66.7% with a very good partial response rate of 54.2%, according to data from a phase 1a dose-escalation trial.

According to data presented at IMS 2023, a real-world analysis showed that teclistamab demonstrated comparable efficacy to the results observed in the phase 2 MajesTec-1 trial for patients with relapsed/refractory multiple myeloma.